Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
provision); profit after tax fell 14% YoY to ?1,210 crore, pressured by lower lenalidomide sales and pricing erosion in U.S./Europe despite double-digit growth in the base business excluding lenalidomide. Pipeline and deals: Dr. Reddy's advanced key programs—semaglutide has India marketing authorization with a planned launch on March 21 and a potential Canada launch between end-Feb and May pending Health Canada, abatacept IV BLA was filed in Dec 2025 and EU/US timelines were outlined—and the company struck a commercialization collaboration with Immutep for eftilagimod alpha with $20m upfront and up to $350m in milestones. Regional mix: North America generics revenue fell 16% YoY (mainly lenalidomide and price erosion), while India grew 19% and emerging markets jumped 32%, helping offset the U.S. decline; the company continues to add new launches and file numerous global filings to support growth. Interested in Dr. Reddy's Laboratories Ltd? Here are five stocks we like better.
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "buy (b-)" rating to a "hold (c+)" rating.MarketBeat
- Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.Business Wire
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesBusiness Wire
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 1/22/26 - Form 6-K
- 1/21/26 - Form 6-K
- 1/21/26 - Form 6-K
- RDY's page on the SEC website